- Home
- STTK vs ACHV Comparison
STTK vs ACHV Comparison
Compare STTK & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ACHV
- Stock Information
- Founded
- STTK 2016
- ACHV N/A
- Country
- STTK United States
- ACHV United States
- Employees
- STTK N/A
- ACHV N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STTK Health Care
- ACHV Health Care
- Exchange
- STTK Nasdaq
- ACHV Nasdaq
- Market Cap
- STTK 37.6M
- ACHV 72.5M
- IPO Year
- STTK 2020
- ACHV N/A
- Fundamental
- Price
- STTK $0.82
- ACHV $2.75
- Analyst Decision
- STTK Hold
- ACHV Strong Buy
- Analyst Count
- STTK 4
- ACHV 3
- Target Price
- STTK $3.00
- ACHV $14.33
- AVG Volume (30 Days)
- STTK 480.9K
- ACHV 1.7M
- Earning Date
- STTK 07-31-2025
- ACHV 08-12-2025
- Dividend Yield
- STTK N/A
- ACHV N/A
- EPS Growth
- STTK N/A
- ACHV N/A
- EPS
- STTK N/A
- ACHV N/A
- Revenue
- STTK $4,606,000.00
- ACHV N/A
- Revenue This Year
- STTK N/A
- ACHV N/A
- Revenue Next Year
- STTK N/A
- ACHV N/A
- P/E Ratio
- STTK N/A
- ACHV N/A
- Revenue Growth
- STTK 69.65
- ACHV N/A
- 52 Week Low
- STTK $0.69
- ACHV $1.84
- 52 Week High
- STTK $4.99
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- STTK 41.99
- ACHV 49.29
- Support Level
- STTK $0.75
- ACHV $2.25
- Resistance Level
- STTK $0.85
- ACHV $2.39
- Average True Range (ATR)
- STTK 0.08
- ACHV 0.23
- MACD
- STTK -0.01
- ACHV -0.03
- Stochastic Oscillator
- STTK 17.95
- ACHV 39.47
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.